Antiarrhythmic drug prophylaxis is known to improve long-term success of electrical cardioversion (CV) in persistent atrial fibrillation (AF). This prospective study evaluates the efficacy of sequential antiarrhythmic drug therapy in sinus rhythm (SR) maintenance after successful elective CV in patients with persistent nonvalvular AF. Materials and Methods: One hundred and twenty-eight patients (61 ± 8 years old) with persistent AF underwent CV. Mean AF duration preceding CV was 268 ± 99 days. Following SR restoration, patients were treated sequentially with either of the following antiarrhythmic drugs: propafenone, sotalol or disopyramide. Where arrhythmia recurred, patients received another CV and a new drug from the range defined above. Where such treatment failed, patients were loaded with 14.0- to16.0-gram doses of amiodarone and a third CV was performed. If the first CV failed to restore SR, patients received a loading dose of amiodarone followed by another CV. When successful, amiodarone was administered on continuous basis. Results: The first CV proved successful in 55.5% of patients. During 1-year of follow-up, 31 patients (43.7%) presented with SR were treated with one antiarrhythmic agent (median does not exist). Application of the second drug proved to be effective in 6 patients (15.0%; median 13 days). Amiodarone was administered as the third antiarrhythmic agent to patients who had AF recurrence on the first two antiarrhythmic agents (propafenone, sotalol or disopyramide). It proved to be effective in 18 patients (52.9%; median does not exist) remaining free from AF for a period of 1 year as of commencement of the sequential antiarrhythmic therapy. Fifty-seven patients, in whom the first CV was ineffective, received amiodarone. During the loading period, SR was restored in 7 patients (12.3%). The remaining 50 patients underwent repeated CV, with SR restored in 37 (74.0%) of them. Long-term amiodarone treatment maintained SR in 30 (68.2%) patients during the follow-up period. Amiodarone helped to maintain SR in a total of 56.5% of patients. Conclusions: Amiodarone seems to be the drug most effectively restoring and maintaining SR in patients with persistent AF resistant to CV and standard antiarrhythmic drug prophylaxis.

Keywords:
Amiodarone, Atrial fibrillation, Antiarrhythmic treatment, Cardioversion
1.
Pritchett ELC: Management of atrial fibrillation. N Engl J Med 1992;326:1264–1271.
2.
Coplen SE, Antman EM, Berlin JA, Hewitt P, Chalmers TC: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation 1990;82:1106–1116.
3.
Flaker GC, Blackshear JL, McBride R, et al: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527–532.
4.
Reimond SC, Chalmers TC, Berlin JA, et al: Assessment of the efficacy and safety of antiarrhythmic therapy for chronic atrial fibrillation: Observation on the role of trial design and implications of drug-related mortality. Am Heart J 1992;124:924.
5.
Friedman LP, Stevenson WG: Proarrhythmia. Am J Cardiol 1998;82:50N–58N.
6.
Roy D, Talaijc M, Dorian P, et al: Amiodarone to prevent recurrence of atrial fibrillation. Canadian Trial of Atrial Fibrillation Investigators. N Engl J Med 2000;342:913–920.
7.
Gosselink ATG, Crijns HJGM, Van Gelder IC, et al: Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992;267:3289–3292.
8.
Crijns HJGM, Van Gelder IC, Van Glist WH, et al: Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for persistent atrial fibrillation or flutter. Am J Cardiol 1991;68:335–341.
9.
Opolski G, Torbicki A, Kosior DA, Szulc M, Wożakowska-Kapon B, Kołodziej P, Achremczyk P, Investigators of the Polish HOT CAFE Trial: Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: The Results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) Study. Chest 2004;126:476–486.
10.
Dreifus LS, Fisch C, Griffin JC, Gillette PC, Mason JW, Parsonnet V: Guidelines for implantation of cardiac pacemakers and antiarrhythmic devices: A report of the American College of Cardiology/American Heart Association task Force of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Pacemaker Implantation). Circulation 1991;84:455–467.
11.
Laupacis A, Albers G, Dalen J, Dunn MI, Jacobson AK: Antithrombotic therapy in atrial fibrillation. Chest 1995;108:352–359.
12.
Stanton MS, Prystowsky EN, Fineberg NS, et al: Arrhythmogenic drugs: A study of 506 patients treated for ventricular tachycardia or fibrillation. J Am Coll Cardiol 1989;14:200–215.
13.
Opolski G, Stanislawska J, Górecki A, et al: Amiodarone in restoration and maintenance of sinus rhythm in patients with chronic atrial fibrillation after unsuccessful direct-current electrical cardioversion. Clin Cardiol 1997;20:337–340.
14.
Bramah NS: Amiodarone: The expanding antiarrhythmic role and how to follow a patient on chronic therapy. Clin Cardiol 1997;20:608–618.
15.
Stafford RS, Robson DC, Misra B, et al: Rate control and sinus rhythm maintenance in atrial fibrillation: National trends in medication use, 1980–1996. Arch Intern Med 1998;158:2144–2148.
16.
Van Gelder IC, Crijns HJGM, Tieleman RG, et al: Chronic atrial fibrillation. Success of serial electrical cardioversion therapy and safety of oral anticoagulation. Arch Intern Med 1996;156:2585–2592.
17.
Brodsky MA, Allen BJ, Walker CJ, Casey TP, Luchet CR, Henry WL: Amiodarone for maintenance of sinus rhythm after electrical cardioversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987;60:572–575,
18.
Gold RL, Haffajee CI, Charos K, Sloan K, Baker K, Baker S, Alpert JS: Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986;57:124–127.
19.
Middlekauff HR, Wiener J, Stevenson WG: Low-dose amiodarone for atrial fibrillation. Am J Cardiol 1993;72:75F–81F.
20.
Horowitz LN, Spielman SN, Greenspan AM, Mintz GS, Morganroth J, Brown R, Brady PM, Kay HR: Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 1985;6:1402–1406.
21.
Sagrista-Sauleda J, Permanyer-Miralda G, Soler-Soler J: Electrical cardioversion after amiodarone administration. Am Heart J 1992;267:1536–1542.
22.
Chun SA, Sager PT, Stevenson WG, Nademanee K, Middlekauff HR, Singh BN: Long-term efficacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995;76:47–50.
23.
Maintenance of sinus rhythm in patients with atrial fibrillation. An AFFIRM substudy of the first antiarrhythmic drug. JACC 2003;42:20–29.
24.
Juul-Moller S, Edvardsson N, Ahlberg NR: Sotalol versus quinidine for the maintenance of sinus rhythm after direct-current electrical cardioversion of atrial fibrillation. Circulation 1990;82:1932–1941.
25.
Antman EM, Beamer AD, Cantillon C, et al: Therapy of refractory atrial fibrillation and atrial flutter: A staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990;15:698–707.
26.
Martin A, Benbow LJ, Leach C, Bailey RJ: Comparison of amiodarone and disopyramide in the control of paroxysmal atrial fibrillation and flutter. Br J Clin Pract Suppl 1986;40:52–60.
27.
Van Gelder IC, Crijns HJGM, Van Gilst WH, et al: Efficacy and safety of flecainid acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 1989;64:317–321.
28.
Nacarelli GV, Dorian P, Hohnloser SH, et al: Prospective comparison of flecainid versus quinidine for treatment of paroxysmal atrial fibrillation or flutter. Am J Cardiol 1996;77:A53–A59.
29.
Podrid PJ, Lown B: Amiodarone therapy in symptomatic, sustained refractory atrial and ventricular tachyarrhythmias. Am Heart J 1981;101:374–379.
30.
Fogoros RN, Anderson KP, Winkle RA, Swerdlow CD, Mason JW: Amiodarone: Clinical efficacy and toxicity in 96 patients with recurrent drug-refractory arrhythmias. Circulation 1983;63:88–94.
31.
Peter T, Hamer A, Mandel WJ, Weiss D: Evaluation of amiodarone therapy in the treatment of drug-resistant cardiac arrhythmias: Follow-up. Am Heart J 1983;106:943–950.
32.
Reader EA, Podrid PJ, Lown B: Side effects and complications of amiodarone therapy. Am Heart J 1985;109:975–978.
33.
Smith WM, Lubbe WF, Whitlock RM, Mercer J, Rutherford JD, Roche AH: Long-term tolerance of amiodarone treatment for cardiac arrhythmias. Am J Cardiol 1986;57:1288–1293.
34.
Vorperian VR, Havighurst TC, Miller S, January CT: Adverse effects of low dose amiodarone: Meta-analysis, J Am Coll Cardiol 1997;30:791–798.
35.
Mason JW: Amiodarone. N Engl J Med 1987;316:455–466.
36.
Kosior D, Karpiński G, Wretowski D, Stolarz P, Stawicki S, Rabczenko D, Torbicki A, Opolski G: Sequential prophylactic antiarrhythmic therapy for maintenance of sinus rhythm after cardioversion of persistent atrial fibrillation one-year follow-up. Kardiol Pol 2002;56:368–374.
© 2005 S. Karger AG, Basel
2005
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.